REMS In-Person Prescription Requirement

Summary#

This bill would stop any FDA REMS-certified provider from prescribing, dispensing, or giving mifepristone or other drugs the bill defines as “abortion drugs” without an in-person visit with the patient. It would also bar such providers from prescribing to patients who live in a State where the provider does not hold a medical license. Violations would cost the provider their REMS-certified status for at least two years. The bill also requires an annual report to Congress listing providers who lost REMS-certified status for these violations or for “improper or unsafe prescribing.”

  • Main change: REMS-certified providers must have an in-person visit with the patient before prescribing mifepristone and must be licensed in the patient’s State.
  • Penalty: Losing REMS-certified status for at least two years for knowingly violating those rules.
  • Reporting: Health and Human Services must send Congress a yearly list of providers who lost REMS status for these reasons.
  • Definition: The bill defines “abortion drug” broadly to include any drug used to intentionally end a pregnancy (with some exceptions).
  • What is unclear: The bill does not define how HHS will decide if a provider “knowingly” violated the rule, what counts as an acceptable in-person visit, or how the “improper or unsafe prescribing” standard will be applied.

What it means for you#

  • REMS-certified health care providers: They must see patients in person before prescribing mifepristone or similar drugs. If they treat patients who live in a State where the provider is not licensed, they risk losing REMS certification for at least two years. This affects prescribing, dispensing, and administering those drugs.
  • Patients seeking mifepristone: This could mean you must attend an in-person visit with a REMS-certified provider in order to receive the drug. Getting the drug by mail or from a provider located in another State could be blocked if the provider is not licensed in your State.
  • Telemedicine services: The bill would limit or prohibit prescribing by remote visits across State lines for these drugs, because providers must be licensed in the patient’s State and must have done an in-person visit.
  • State-licensed providers and clinics: Clinics that serve patients from other States may need to check licensing rules carefully or refer patients to locally licensed providers.
  • HHS / FDA: The agency must track and report annually to Congress which REMS-certified providers lost certification for violations or unsafe prescribing.

Expenses#

No publicly available information on an official cost estimate is included in the bill text.

  • The bill would create administrative work for HHS to maintain records and produce the annual report.
  • Providers and clinics may face costs to change practices (more in-person visits), obtain additional State licenses, or handle lost REMS certification.
  • Patients may face added travel or time costs if they must attend in-person visits locally.
  • Enforcement and compliance monitoring could require agency staff time; the bill does not estimate those costs.

Proponents' View#

  • The bill appears intended to increase patient safety by requiring in-person clinical evaluation before prescribing drugs used to terminate pregnancy.
  • It frames REMS as a safety tool and would tie certification to compliance with in-person and licensure rules.
  • Supporters may see the annual reporting requirement as a way to increase oversight and accountability of providers who prescribe these drugs.

Opponents' View#

  • One concern is that the in-person and in-State license requirements could reduce access to care, especially for people in rural areas or where local providers are scarce.
  • The rule would limit telemedicine prescribing and mail delivery options that some patients currently use.
  • It is unclear how “knowingly” violating the rule will be proved, and the bill does not explain the process for removing or restoring REMS-certified status.
  • The bill does not specify what counts as an acceptable in-person visit, nor how temporary or cross-state residency is handled.
  • There is no cost estimate in the bill text, so the budgetary impact on agencies, clinics, and patients is not defined.